AbbVie Inc. (ABBV)
| Market Cap | 351.09B |
| Revenue (ttm) | 57.37B |
| Net Income (ttm) | 4.16B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.34 |
| PE Ratio | 84.82 |
| Forward PE | 15.58 |
| Dividend | $6.56 (3.31%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 6,424,512 |
| Open | 195.84 |
| Previous Close | 193.34 |
| Day's Range | 194.70 - 198.96 |
| 52-Week Range | 153.58 - 218.66 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 212.00 (+6.82%) |
| Earnings Date | Apr 25, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $212.0, which is an increase of 6.82% from the latest price.
News
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"
BOTOX® Cosmetic Will Provide 250 Entrepreneurs with Access to New Resources and Opportunities and Will Award 20 Grants Worth $20,000 Each to Support Business Goals. By 2030, BOTOX® Cosmetic Pledges to...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Final Trades: Netflix, Abbvie, iShares U.S. Industrials ETF and Sherwin Williams
The Fast Money team just dropped their Final Trades — find out what's catching their eye now!
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next?
AbbVie Inc. ABBV is trading higher Tuesday. The stock has been in an uptrend.
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
– RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults – Also known as temporal arteritis, GCA is the most common vas...
S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report
Major U.S. equities indexes were mixed on the first day of a new trading week that will feature earnings reports from a slew of major corporations.
Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its onco...
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
AbbVie's First Quarter Beat And Raise Leaves Room For More
AbbVie Inc. beat first-quarter revenue and EPS estimates and raised the full-year EPS guidance by $0.10 and revenue guidance by $700 million. Skyrizi and Rinvoq drove the ABBV Q1 beat with exceptional...
AbbVie: Q1 Earnings Reinforce Positive Momentum
AbbVie Inc.'s Q1 2025 results exceeded expectations on the earnings front, but the key question is whether the stock is an immediate buy. It saw an accelerated 8.4% YoY revenue growth, driven by stron...
Drugmaker AbbVie says tax reform, not tariffs, would drive U.S. manufacturing
AbbVie Inc. took a little shot at the Trump administration's trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing.
AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside
AbbVie Inc.'s Q1 earnings show an 8.4% revenue increase, driven by strong performance in immunology, neuroscience, and oncology divisions, with Skyrizi and Rinvoq leading growth. Despite Humira's pate...
AbbVie Stock Rises on Stronger-Than-Expected Results, Profit Outlook Lift
AbbVie (ABBV) on Friday reported first-quarter results that came in above analysts' estimates, and lifted its full-year profit guidance.
AbbVie Inc. (ABBV) Q1 2025 Earnings Call Transcript
AbbVie Inc. (NYSE:ABBV) Q1 2025 - Earnings Conference Call April 25, 2025 9:00 PM ET Company Participants Liz Shea - Senior VP, IR Rob Michael - CEO Jeff Stewart - EVP, Chief Commercial Officer Roopa...
ABBV Earnings Beat, Exposure to Tariffs, ABBV & UNH Options Trades
David Kaplan says AbbVie (ABBV) shows "unusually strong growth compared to peers." While he notes parts of its business is exposed to tariffs, the pharmaceutical and medical device industries are typi...
AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector
AbbVie Inc.'s ABBV stock is trading higher after it released better-than-expected Q1 earnings and raised its 2025 forecast.
AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet.
First-quarter adjusted earnings per share were $2.46 on sales of $13.3 billion, above analysts' expectations.
AbbVie lifts profit forecast on strong sales of newer immunology drugs
AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped the company beat Wall Street estimates for first-quarter earnings.
AbbVie Reports First-Quarter 2025 Financial Results
Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 P...
AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effe...
Final Trades: 3M, Abbvie, Salesforce and Intuitive Surgical
The Investment Committee give you their top stocks to watch for the second half.
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys
March investments totaled around $1,200, mainly in BDCs like Blue Owl Capital and Ares Capital, boosting annual dividend income by $100. Dividend income hit a new all-time record of $1,404, up 17% Y/Y...